Heart Failure Reviews

Papers
(The TQCC of Heart Failure Reviews is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Heart failure and COVID-19140
Biomarkers for the diagnosis and management of heart failure133
COVID-19 and myocarditis: a systematic review and overview of current challenges116
Machine learning versus conventional clinical methods in guiding management of heart failure patients—a systematic review54
Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment53
Extracellular matrix–based biomaterials for cardiac regeneration and repair44
Mechanisms of COVID-19-induced heart failure: a short review44
Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments42
SGLT2-inhibitors; more than just glycosuria and diuresis42
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets41
Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers41
Polypharmacy definition and prevalence in heart failure: a systematic review41
Clinical inertia in the treatment of heart failure: a major issue to tackle40
Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system—from molecular mechanisms to therapeutic applications38
The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis34
The Elabela-APJ axis: a promising therapeutic target for heart failure33
Therapeutic angiogenesis with exosomal microRNAs: an effectual approach for the treatment of myocardial ischemia33
The role and molecular mechanism of epigenetics in cardiac hypertrophy31
The role of non-invasive devices for the telemonitoring of heart failure patients29
Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness27
Detection of myocardial fibrosis by speckle-tracking echocardiography: from prediction to clinical applications26
Resistance training in heart failure patients: a systematic review and meta-analysis26
Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress26
Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges25
A meta-analysis of microRNA expression profiling studies in heart failure25
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors23
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials23
Cardiogenic shock and acute kidney injury: the rule rather than the exception22
The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced eject22
Immunity and inflammation: the neglected key players in congenital heart disease?22
Mechanisms underlying the pathophysiology of heart failure with preserved ejection fraction: the tip of the iceberg22
Multiple roles of cardiac macrophages in heart homeostasis and failure22
Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 202121
Current and emerging drug targets in heart failure treatment21
Ventricular non-compaction review21
The non-invasive assessment of myocardial work by pressure-strain analysis: clinical applications21
Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials20
Cardiorenal syndrome: long road between kidney and heart20
Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases20
Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure19
Effect of exercise on epicardial adipose tissue in adults: a systematic review and meta-analyses19
Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide19
Left ventricular hypertrophy and sudden cardiac death19
The roles of epicardial adipose tissue in heart failure19
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure18
Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions18
Filamin C in cardiomyopathy: from physiological roles to DNA variants18
Palliative care needs-assessment and measurement tools used in patients with heart failure: a systematic mixed-studies review with narrative synthesis18
SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms18
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism18
Pirfenidone as a novel cardiac protective treatment17
Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis17
Management of RAASi-associated hyperkalemia in patients with cardiovascular disease17
Heart–lung interactions in COVID-19: prognostic impact and usefulness of bedside echocardiography for monitoring of the right ventricle involvement17
SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis16
The use of diflunisal for transthyretin cardiac amyloidosis: a review16
Machine learning and statistical methods for predicting mortality in heart failure16
Device-based treatment options for heart failure with preserved ejection fraction16
Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis16
The protective effects of 17-β estradiol and SIRT1 against cardiac hypertrophy: a review16
Cardiac complications in inherited mitochondrial diseases15
Creatine deficiency and heart failure15
Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review15
Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure15
Cardiac xenotransplantation: a promising way to treat advanced heart failure15
Lung ultrasound–guided management to reduce hospitalization in chronic heart failure: a systematic review and meta-analysis15
Balloon pulmonary angioplasty vs. pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis14
Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a meta-analysis of randomized controlled trials14
Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction14
Right ventricular phenotype, function, and failure: a journey from evolution to clinics14
Transplant and mechanical circulatory support in patients with adult congenital heart disease14
The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review14
Remote monitoring for heart failure using implantable devices: a systematic review, meta-analysis, and meta-regression of randomized controlled trials14
New antidiabetic therapy and HFpEF: light at the end of tunnel?13
Peripartum cardiomyopathy: a review13
Efficacy of motivational interviewing on enhancing self-care behaviors among patients with chronic heart failure: a systematic review and meta-analysis of randomized controlled trials13
0.022520065307617